1.
Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma.
Sterling Jacob, Hua Peiying, Dunaief Joshua L, Cui Qi N, VanderBeek Brian L
Br J OphthalmolAug 202149 citationsCohort Study
GLP-1R agonist use for diabetes was studied and found to significantly reduce glaucoma risk. This suggests these drugs may offer a new strategy for glaucoma prevention.